COVID-19 Impact on Global Neuroblastoma Drugs Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-neuroblastoma-drugs-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global Neuroblastoma Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neuroblastoma Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Pfizer
- Teva Pharmaceutical
- Johnson & Johnson
- Bristol-Myers Squibb
- United Therapeutics
- Chemotherapy
- Immunotherapy
- Others
- Hospitals
- Clinics
- Others
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Neuroblastoma Drugs status, future forecast, growth opportunity, key market and key players.
- To present the Neuroblastoma Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuroblastoma Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Neuroblastoma Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Immunotherapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Neuroblastoma Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Neuroblastoma Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Neuroblastoma Drugs Industry
1.6.1.1 Neuroblastoma Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Neuroblastoma Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Neuroblastoma Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Neuroblastoma Drugs Market Perspective (2015-2026)
2.2 Neuroblastoma Drugs Growth Trends by Regions
2.2.1 Neuroblastoma Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neuroblastoma Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Neuroblastoma Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neuroblastoma Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Neuroblastoma Drugs Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Neuroblastoma Drugs Players by Market Size
3.1.1 Global Top Neuroblastoma Drugs Players by Revenue (2015-2020)
3.1.2 Global Neuroblastoma Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Neuroblastoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neuroblastoma Drugs Market Concentration Ratio
3.2.1 Global Neuroblastoma Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neuroblastoma Drugs Revenue in 2019
3.3 Neuroblastoma Drugs Key Players Head office and Area Served
3.4 Key Players Neuroblastoma Drugs Product Solution and Service
3.5 Date of Enter into Neuroblastoma Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Neuroblastoma Drugs Historic Market Size by Type (2015-2020)
4.2 Global Neuroblastoma Drugs Forecasted Market Size by Type (2021-2026)
5 NEUROBLASTOMA DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Neuroblastoma Drugs Market Size by Application (2015-2020)
5.2 Global Neuroblastoma Drugs Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Neuroblastoma Drugs Market Size (2015-2020)
6.2 Neuroblastoma Drugs Key Players in North America (2019-2020)
6.3 North America Neuroblastoma Drugs Market Size by Type (2015-2020)
6.4 North America Neuroblastoma Drugs Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Neuroblastoma Drugs Market Size (2015-2020)
7.2 Neuroblastoma Drugs Key Players in Europe (2019-2020)
7.3 Europe Neuroblastoma Drugs Market Size by Type (2015-2020)
7.4 Europe Neuroblastoma Drugs Market Size by Application (2015-2020)
8 CHINA
8.1 China Neuroblastoma Drugs Market Size (2015-2020)
8.2 Neuroblastoma Drugs Key Players in China (2019-2020)
8.3 China Neuroblastoma Drugs Market Size by Type (2015-2020)
8.4 China Neuroblastoma Drugs Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Neuroblastoma Drugs Market Size (2015-2020)
9.2 Neuroblastoma Drugs Key Players in Japan (2019-2020)
9.3 Japan Neuroblastoma Drugs Market Size by Type (2015-2020)
9.4 Japan Neuroblastoma Drugs Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Neuroblastoma Drugs Market Size (2015-2020)
10.2 Neuroblastoma Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neuroblastoma Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Neuroblastoma Drugs Market Size by Application (2015-2020)
11 INDIA
11.1 India Neuroblastoma Drugs Market Size (2015-2020)
11.2 Neuroblastoma Drugs Key Players in India (2019-2020)
11.3 India Neuroblastoma Drugs Market Size by Type (2015-2020)
11.4 India Neuroblastoma Drugs Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Neuroblastoma Drugs Market Size (2015-2020)
12.2 Neuroblastoma Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Neuroblastoma Drugs Market Size by Type (2015-2020)
12.4 Central & South America Neuroblastoma Drugs Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview and Its Total Revenue
13.1.3 Pfizer Neuroblastoma Drugs Introduction
13.1.4 Pfizer Revenue in Neuroblastoma Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Teva Pharmaceutical
13.2.1 Teva Pharmaceutical Company Details
13.2.2 Teva Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Teva Pharmaceutical Neuroblastoma Drugs Introduction
13.2.4 Teva Pharmaceutical Revenue in Neuroblastoma Drugs Business (2015-2020)
13.2.5 Teva Pharmaceutical Recent Development
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Details
13.3.2 Johnson & Johnson Business Overview and Its Total Revenue
13.3.3 Johnson & Johnson Neuroblastoma Drugs Introduction
13.3.4 Johnson & Johnson Revenue in Neuroblastoma Drugs Business (2015-2020)
13.3.5 Johnson & Johnson Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.4.3 Bristol-Myers Squibb Neuroblastoma Drugs Introduction
13.4.4 Bristol-Myers Squibb Revenue in Neuroblastoma Drugs Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
13.5 United Therapeutics
13.5.1 United Therapeutics Company Details
13.5.2 United Therapeutics Business Overview and Its Total Revenue
13.5.3 United Therapeutics Neuroblastoma Drugs Introduction
13.5.4 United Therapeutics Revenue in Neuroblastoma Drugs Business (2015-2020)
13.5.5 United Therapeutics Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuroblastoma Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Neuroblastoma Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Immunotherapy
1.4.4 Others
1.5 Market by Application
1.5.1 Global Neuroblastoma Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Neuroblastoma Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Neuroblastoma Drugs Industry
1.6.1.1 Neuroblastoma Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Neuroblastoma Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Neuroblastoma Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Neuroblastoma Drugs Market Perspective (2015-2026)
2.2 Neuroblastoma Drugs Growth Trends by Regions
2.2.1 Neuroblastoma Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neuroblastoma Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Neuroblastoma Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neuroblastoma Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Neuroblastoma Drugs Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Neuroblastoma Drugs Players by Market Size
3.1.1 Global Top Neuroblastoma Drugs Players by Revenue (2015-2020)
3.1.2 Global Neuroblastoma Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Neuroblastoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neuroblastoma Drugs Market Concentration Ratio
3.2.1 Global Neuroblastoma Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neuroblastoma Drugs Revenue in 2019
3.3 Neuroblastoma Drugs Key Players Head office and Area Served
3.4 Key Players Neuroblastoma Drugs Product Solution and Service
3.5 Date of Enter into Neuroblastoma Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Neuroblastoma Drugs Historic Market Size by Type (2015-2020)
4.2 Global Neuroblastoma Drugs Forecasted Market Size by Type (2021-2026)
5 NEUROBLASTOMA DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Neuroblastoma Drugs Market Size by Application (2015-2020)
5.2 Global Neuroblastoma Drugs Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Neuroblastoma Drugs Market Size (2015-2020)
6.2 Neuroblastoma Drugs Key Players in North America (2019-2020)
6.3 North America Neuroblastoma Drugs Market Size by Type (2015-2020)
6.4 North America Neuroblastoma Drugs Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Neuroblastoma Drugs Market Size (2015-2020)
7.2 Neuroblastoma Drugs Key Players in Europe (2019-2020)
7.3 Europe Neuroblastoma Drugs Market Size by Type (2015-2020)
7.4 Europe Neuroblastoma Drugs Market Size by Application (2015-2020)
8 CHINA
8.1 China Neuroblastoma Drugs Market Size (2015-2020)
8.2 Neuroblastoma Drugs Key Players in China (2019-2020)
8.3 China Neuroblastoma Drugs Market Size by Type (2015-2020)
8.4 China Neuroblastoma Drugs Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Neuroblastoma Drugs Market Size (2015-2020)
9.2 Neuroblastoma Drugs Key Players in Japan (2019-2020)
9.3 Japan Neuroblastoma Drugs Market Size by Type (2015-2020)
9.4 Japan Neuroblastoma Drugs Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Neuroblastoma Drugs Market Size (2015-2020)
10.2 Neuroblastoma Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neuroblastoma Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Neuroblastoma Drugs Market Size by Application (2015-2020)
11 INDIA
11.1 India Neuroblastoma Drugs Market Size (2015-2020)
11.2 Neuroblastoma Drugs Key Players in India (2019-2020)
11.3 India Neuroblastoma Drugs Market Size by Type (2015-2020)
11.4 India Neuroblastoma Drugs Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Neuroblastoma Drugs Market Size (2015-2020)
12.2 Neuroblastoma Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Neuroblastoma Drugs Market Size by Type (2015-2020)
12.4 Central & South America Neuroblastoma Drugs Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview and Its Total Revenue
13.1.3 Pfizer Neuroblastoma Drugs Introduction
13.1.4 Pfizer Revenue in Neuroblastoma Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Teva Pharmaceutical
13.2.1 Teva Pharmaceutical Company Details
13.2.2 Teva Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Teva Pharmaceutical Neuroblastoma Drugs Introduction
13.2.4 Teva Pharmaceutical Revenue in Neuroblastoma Drugs Business (2015-2020)
13.2.5 Teva Pharmaceutical Recent Development
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Details
13.3.2 Johnson & Johnson Business Overview and Its Total Revenue
13.3.3 Johnson & Johnson Neuroblastoma Drugs Introduction
13.3.4 Johnson & Johnson Revenue in Neuroblastoma Drugs Business (2015-2020)
13.3.5 Johnson & Johnson Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.4.3 Bristol-Myers Squibb Neuroblastoma Drugs Introduction
13.4.4 Bristol-Myers Squibb Revenue in Neuroblastoma Drugs Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
13.5 United Therapeutics
13.5.1 United Therapeutics Company Details
13.5.2 United Therapeutics Business Overview and Its Total Revenue
13.5.3 United Therapeutics Neuroblastoma Drugs Introduction
13.5.4 United Therapeutics Revenue in Neuroblastoma Drugs Business (2015-2020)
13.5.5 United Therapeutics Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Neuroblastoma Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Neuroblastoma Drugs Revenue
Table 3. Ranking of Global Top Neuroblastoma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Neuroblastoma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Immunotherapy
Table 7. Key Players of Others
Table 8. COVID-19 Impact Global Market: (Four Neuroblastoma Drugs Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Neuroblastoma Drugs Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Neuroblastoma Drugs Players to Combat Covid-19 Impact
Table 13. Global Neuroblastoma Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global Neuroblastoma Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Neuroblastoma Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Neuroblastoma Drugs Market Share by Regions (2015-2020)
Table 17. Global Neuroblastoma Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Neuroblastoma Drugs Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Neuroblastoma Drugs Market Growth Strategy
Table 23. Main Points Interviewed from Key Neuroblastoma Drugs Players
Table 24. Global Neuroblastoma Drugs Revenue by Players (2015-2020) (Million US$)
Table 25. Global Neuroblastoma Drugs Market Share by Players (2015-2020)
Table 26. Global Top Neuroblastoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroblastoma Drugs as of 2019)
Table 27. Global Neuroblastoma Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Neuroblastoma Drugs Product Solution and Service
Table 30. Date of Enter into Neuroblastoma Drugs Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 33. Global Neuroblastoma Drugs Market Size Share by Type (2015-2020)
Table 34. Global Neuroblastoma Drugs Revenue Market Share by Type (2021-2026)
Table 35. Global Neuroblastoma Drugs Market Size Share by Application (2015-2020)
Table 36. Global Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 37. Global Neuroblastoma Drugs Market Size Share by Application (2021-2026)
Table 38. North America Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 40. North America Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 41. North America Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 42. North America Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 43. North America Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 44. Europe Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 46. Europe Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 47. Europe Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 48. Europe Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 49. Europe Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 50. China Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 51. China Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 52. China Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 53. China Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 54. China Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 55. China Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 56. Japan Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 58. Japan Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 59. Japan Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 60. Japan Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 61. Japan Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 64. Southeast Asia Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 66. Southeast Asia Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 68. India Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 69. India Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 70. India Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 71. India Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 72. India Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 73. India Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 74. Central & South America Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 76. Central & South America Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 78. Central & South America Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 80. Pfizer Company Details
Table 81. Pfizer Business Overview
Table 82. Pfizer Product
Table 83. Pfizer Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 84. Pfizer Recent Development
Table 85. Teva Pharmaceutical Company Details
Table 86. Teva Pharmaceutical Business Overview
Table 87. Teva Pharmaceutical Product
Table 88. Teva Pharmaceutical Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 89. Teva Pharmaceutical Recent Development
Table 90. Johnson & Johnson Company Details
Table 91. Johnson & Johnson Business Overview
Table 92. Johnson & Johnson Product
Table 93. Johnson & Johnson Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 94. Johnson & Johnson Recent Development
Table 95. Bristol-Myers Squibb Company Details
Table 96. Bristol-Myers Squibb Business Overview
Table 97. Bristol-Myers Squibb Product
Table 98. Bristol-Myers Squibb Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 99. Bristol-Myers Squibb Recent Development
Table 100. United Therapeutics Company Details
Table 101. United Therapeutics Business Overview
Table 102. United Therapeutics Product
Table 103. United Therapeutics Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 104. United Therapeutics Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 1. Neuroblastoma Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Neuroblastoma Drugs Revenue
Table 3. Ranking of Global Top Neuroblastoma Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Neuroblastoma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Immunotherapy
Table 7. Key Players of Others
Table 8. COVID-19 Impact Global Market: (Four Neuroblastoma Drugs Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Neuroblastoma Drugs Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Neuroblastoma Drugs Players to Combat Covid-19 Impact
Table 13. Global Neuroblastoma Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global Neuroblastoma Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Neuroblastoma Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Neuroblastoma Drugs Market Share by Regions (2015-2020)
Table 17. Global Neuroblastoma Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Neuroblastoma Drugs Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Neuroblastoma Drugs Market Growth Strategy
Table 23. Main Points Interviewed from Key Neuroblastoma Drugs Players
Table 24. Global Neuroblastoma Drugs Revenue by Players (2015-2020) (Million US$)
Table 25. Global Neuroblastoma Drugs Market Share by Players (2015-2020)
Table 26. Global Top Neuroblastoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroblastoma Drugs as of 2019)
Table 27. Global Neuroblastoma Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Neuroblastoma Drugs Product Solution and Service
Table 30. Date of Enter into Neuroblastoma Drugs Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 33. Global Neuroblastoma Drugs Market Size Share by Type (2015-2020)
Table 34. Global Neuroblastoma Drugs Revenue Market Share by Type (2021-2026)
Table 35. Global Neuroblastoma Drugs Market Size Share by Application (2015-2020)
Table 36. Global Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 37. Global Neuroblastoma Drugs Market Size Share by Application (2021-2026)
Table 38. North America Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 40. North America Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 41. North America Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 42. North America Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 43. North America Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 44. Europe Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 46. Europe Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 47. Europe Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 48. Europe Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 49. Europe Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 50. China Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 51. China Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 52. China Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 53. China Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 54. China Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 55. China Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 56. Japan Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 58. Japan Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 59. Japan Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 60. Japan Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 61. Japan Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 64. Southeast Asia Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 66. Southeast Asia Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 68. India Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 69. India Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 70. India Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 71. India Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 72. India Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 73. India Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 74. Central & South America Key Players Neuroblastoma Drugs Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players Neuroblastoma Drugs Market Share (2019-2020)
Table 76. Central & South America Neuroblastoma Drugs Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America Neuroblastoma Drugs Market Share by Type (2015-2020)
Table 78. Central & South America Neuroblastoma Drugs Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America Neuroblastoma Drugs Market Share by Application (2015-2020)
Table 80. Pfizer Company Details
Table 81. Pfizer Business Overview
Table 82. Pfizer Product
Table 83. Pfizer Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 84. Pfizer Recent Development
Table 85. Teva Pharmaceutical Company Details
Table 86. Teva Pharmaceutical Business Overview
Table 87. Teva Pharmaceutical Product
Table 88. Teva Pharmaceutical Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 89. Teva Pharmaceutical Recent Development
Table 90. Johnson & Johnson Company Details
Table 91. Johnson & Johnson Business Overview
Table 92. Johnson & Johnson Product
Table 93. Johnson & Johnson Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 94. Johnson & Johnson Recent Development
Table 95. Bristol-Myers Squibb Company Details
Table 96. Bristol-Myers Squibb Business Overview
Table 97. Bristol-Myers Squibb Product
Table 98. Bristol-Myers Squibb Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 99. Bristol-Myers Squibb Recent Development
Table 100. United Therapeutics Company Details
Table 101. United Therapeutics Business Overview
Table 102. United Therapeutics Product
Table 103. United Therapeutics Revenue in Neuroblastoma Drugs Business (2015-2020) (Million US$)
Table 104. United Therapeutics Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Neuroblastoma Drugs Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Immunotherapy Features
Figure 4. Others Features
Figure 5. Global Neuroblastoma Drugs Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Neuroblastoma Drugs Report Years Considered
Figure 10. Global Neuroblastoma Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Neuroblastoma Drugs Market Share by Regions: 2020 VS 2026
Figure 12. Global Neuroblastoma Drugs Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Neuroblastoma Drugs Market Share by Players in 2019
Figure 15. Global Top Neuroblastoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroblastoma Drugs as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Neuroblastoma Drugs Revenue in 2019
Figure 17. North America Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Pfizer Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 26. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Teva Pharmaceutical Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 28. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Johnson & Johnson Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 30. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Bristol-Myers Squibb Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 32. United Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. United Therapeutics Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 34. Bottom-up and Top-down Approaches for This Report
Figure 35. Data Triangulation
Figure 36. Key Executives Interviewed
Figure 1. Global Neuroblastoma Drugs Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Immunotherapy Features
Figure 4. Others Features
Figure 5. Global Neuroblastoma Drugs Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Neuroblastoma Drugs Report Years Considered
Figure 10. Global Neuroblastoma Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Neuroblastoma Drugs Market Share by Regions: 2020 VS 2026
Figure 12. Global Neuroblastoma Drugs Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Neuroblastoma Drugs Market Share by Players in 2019
Figure 15. Global Top Neuroblastoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroblastoma Drugs as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Neuroblastoma Drugs Revenue in 2019
Figure 17. North America Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Neuroblastoma Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Pfizer Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 26. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Teva Pharmaceutical Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 28. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Johnson & Johnson Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 30. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Bristol-Myers Squibb Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 32. United Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. United Therapeutics Revenue Growth Rate in Neuroblastoma Drugs Business (2015-2020)
Figure 34. Bottom-up and Top-down Approaches for This Report
Figure 35. Data Triangulation
Figure 36. Key Executives Interviewed